STOCK TITAN
  1. Home
  2. Sec-filings
  3. AGEN
  4. [Form 4] AGENUS INC Insider Trading Activity

Agenus (NASDAQ: AGEN) director Armen paid salary in stock grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

ARMEN GARO H reported acquisition or exercise transactions in this Form 4 filing.

Agenus Inc. director and officer Garo H. Armen received 3,983 shares of Common Stock as fully vested compensation, in lieu of cash salary, for the pay period ending March 20, 2026. The shares were valued at $3.71, the closing price on March 20, 2026, and issued under the Amended and Restated Agenus Inc. 2019 Equity Incentive plan. Following the grant, he holds 334,518 shares directly, plus additional indirect holdings through IRA accounts and entities including the Garo Armen 2020 2 Year AG GRAT and Pixie Partners.

Positive

  • None.

Negative

  • None.
Insider ARMEN GARO H
Role See Remarks
Type Security Shares Price Value
Grant/Award Common Stock 3,983 $3.71 $15K
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 334,518 shares (Direct); Common Stock — 31,298 shares (Indirect, See Footnote)
Footnotes (1)
  1. At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending March 20, 2026. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance. $3.71 is the closing price of our Common Stock on March 20, 2026, the last trading day for the payroll date for the pay period ending March 20, 2026. Shares are held in Dr. Armen's IRA accounts. Dr. Armen is trustee and has investment authority for the Garo Armen 2020 2 Year AG GRAT holder of 23,950 shares of our Common Stock. Dr. Armen is a general partner in Pixie Partners, a General Partnership ("Pixie"), which as of the date of this report owns 5,000 shares of our Common Stock. Dr. Armen has a pecuniary interest in only a portion of the shares held by Pixie and disclaims beneficial ownership to the extent of his pecuniary interest therein.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
ARMEN GARO H
(Last)(First)(Middle)
C/O AGENUS INC.
3 FORBES ROAD
(Street)
LEXINGTON MASSACHUSETTS 02421
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
AGENUS INC [ AGEN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
See Remarks
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
03/20/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock(1)03/20/2026A3,983A$3.71(2)334,518D
Common Stock31,298ISee Footnote(3)
Common Stock28,950ISee Footnote(4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending March 20, 2026. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.
2. $3.71 is the closing price of our Common Stock on March 20, 2026, the last trading day for the payroll date for the pay period ending March 20, 2026.
3. Shares are held in Dr. Armen's IRA accounts.
4. Dr. Armen is trustee and has investment authority for the Garo Armen 2020 2 Year AG GRAT holder of 23,950 shares of our Common Stock. Dr. Armen is a general partner in Pixie Partners, a General Partnership ("Pixie"), which as of the date of this report owns 5,000 shares of our Common Stock. Dr. Armen has a pecuniary interest in only a portion of the shares held by Pixie and disclaims beneficial ownership to the extent of his pecuniary interest therein.
Remarks:
Chairman, Chief Executive Officer and Principal Financial Officer
/s/ Austin Charette, as Attorney-in-Fact for Garo H. Armen03/24/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Agenus (AGEN) report for Garo H. Armen?

Agenus reported that Garo H. Armen received 3,983 shares of Common Stock as a fully vested stock grant, taken as salary in stock rather than cash for the pay period ending March 20, 2026.

Was the Agenus (AGEN) Form 4 transaction an open-market purchase or sale?

The Form 4 shows a grant of 3,983 Agenus shares as compensation, not an open-market purchase or sale. It represents salary paid in stock under the company’s 2019 equity incentive plan, fully vested on issuance.

At what price were the Agenus (AGEN) compensation shares valued for Garo H. Armen?

The 3,983 Agenus shares were valued at $3.71 per share, equal to the closing price of the company’s Common Stock on March 20, 2026, which was the last trading day for the relevant payroll date.

How many Agenus (AGEN) shares does Garo H. Armen hold directly after this grant?

After the compensation grant, Garo H. Armen directly holds 334,518 shares of Agenus Common Stock. This figure reflects his direct ownership position reported as of the Form 4’s transaction date for the March 20, 2026 period.

What indirect Agenus (AGEN) holdings are associated with Garo H. Armen?

Indirect holdings include Agenus shares in Dr. Armen’s IRA accounts and 28,950 shares through the Garo Armen 2020 2 Year AG GRAT and Pixie Partners. He is trustee of the GRAT and a general partner in Pixie, with pecuniary interest only in part of Pixie’s shares.

Why is Garo H. Armen’s salary at Agenus (AGEN) being paid in stock?

At Dr. Armen’s request, and with Compensation Committee approval, his salary is being paid in Agenus stock instead of cash. The 3,983-share grant represents the net amount of his salary for the pay period ending March 20, 2026.